Brief: Bavarian Nordic Reports Positive Topline Data For Mpox/Smallpox Vaccine
07/10/2025 15:58
Oct 7 (Reuters) - Bavarian Nordic A/S BAVA.CO: BAVARIAN NORDIC REPORTS POSITIVE TOPLINE DATA FOR MPOX/SMALLPOX VACCINE IN PEDIATRIC POPULATION REG-BAVARIAN NORDIC REPORTS POSITIVE TOPLINE DATA FOR MPOX/SMALLPOX VACCINE IN PEDIATRIC POPULATION PRIMARY ENDPOINT WAS MET IN CLINICAL STUDY, DEMONSTRATING A COMPARABLE SAFETY PROFILE AND A NON-INFERIOR IMMUNE RESPONSE FOR MVA-BN IN CHILDREN AGED 2-11 YEARS COMPARED TO ADULTS RESULTS WILL SUPPORT FILING FOR LABEL EXTENSION WITH EMA IN 2026 VACCINE WAS GENERALLY WELL TOLERATED IN PEDIATRIC POPULATION, WITH A SAFETY PROFILE SIMILAR TO ADULTS AND NO UNEXPECTED SIGNALS. Source text: ID:nGNE7JGtTZ Further company coverage: BAVA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Bavarian Nordic A/S
See all newsBrief: Bavarian Nordic Gets Smallpox/Mpox Vaccine Supply Contract
Brief: Bavarian Nordic Secures Additional Government Contract For The Supply Of Smallpox/Mpox Vaccine
Brief: Bavarian Nordic Launches Final Tranche Of Buy-Back Program
Bavarian Nordic falls as high costs, lower vaccine sales hit Q1 results
Bavarian Nordic Q1 revenue falls as Public Preparedness unit sales decline